Cathay Biotech Inc. (688065.SH) released its 2024 interim report on August 15th, realizing a revenue of 1.444 billion yuan, up 40.16% year on year; a net profit attributable to shareholders of listed companies of 0.247 billion yuan, up 2.31% year on year; a net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 0.24 billion yuan, up 11.34% year on year; and a basic earnings per share (EPS) of 0.42 yuan.
During the reporting period, the company's revenue increased by 40.16% compared to the same period last year. This is mainly due to the company seizing market opportunities, increasing product sales efforts, and expanding the production capacity of new products such as decanedioic acid. As a result, the sales volume and revenue of long-chain dicarboxylic acids increased significantly compared to the same period last year.